New Risk • Jun 01
New major risk - Revenue and earnings growth Earnings have declined by 3.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 3.1% per year over the past 5 years. High level of non-cash earnings (37% accrual ratio). Minor Risk Market cap is less than US$100m (₩52.0b market cap, or US$34.5m). New Risk • Apr 01
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 36% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (36% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Profit margins are more than 30% lower than last year (18% net profit margin). Market cap is less than US$100m (₩58.6b market cap, or US$38.9m). Duyuru • Mar 17
Aligned Genetics, Inc., Annual General Meeting, Mar 31, 2026 Aligned Genetics, Inc., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: seminar room, 599, gosan-ro, gyeonggi-do, gunpo South Korea New Risk • Feb 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩85.1b market cap, or US$59.5m). Valuation Update With 7 Day Price Move • Feb 25
Investor sentiment improves as stock rises 44% After last week's 44% share price gain to ₩6,050, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 18x in the Life Sciences industry in South Korea. Total returns to shareholders of 40% over the past three years. Valuation Update With 7 Day Price Move • Feb 04
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩4,305, the stock trades at a trailing P/E ratio of 16.2x. Average trailing P/E is 16x in the Life Sciences industry in South Korea. Total returns to shareholders of 6.4% over the past three years. Buy Or Sell Opportunity • Aug 05
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 12% to ₩3,475. The fair value is estimated to be ₩2,882, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.2% over the last 3 years. Earnings per share has declined by 5.5%. Buy Or Sell Opportunity • Jul 11
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 11% to ₩3,350. The fair value is estimated to be ₩2,786, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.2% over the last 3 years. Earnings per share has declined by 5.5%. Buy Or Sell Opportunity • Jun 11
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 14% to ₩3,460. The fair value is estimated to be ₩2,799, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.2% over the last 3 years. Earnings per share has declined by 5.5%. Reported Earnings • Mar 14
Full year 2024 earnings released: EPS: ₩287 (vs ₩450 in FY 2023) Full year 2024 results: EPS: ₩287. Revenue: ₩15.8b (up 3.7% from FY 2023). Net income: ₩4.13b (up 28% from FY 2023). Profit margin: 26% (up from 21% in FY 2023). The increase in margin was primarily driven by higher revenue. Duyuru • Mar 12
Aligned Genetics, Inc., Annual General Meeting, Mar 31, 2025 Aligned Genetics, Inc., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 50, munwoncheonggye 2-gil, gyeonggi-do, gwacheon South Korea Duyuru • Jan 21
Aligned Genetics, Inc. (KOSDAQ:A238120) announces an Equity Buyback for KRW 1,000 million worth of its shares. Aligned Genetics, Inc. (KOSDAQ:A238120) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its common stock pursuant to a trust agreement with IBK SECURITIES CO., LTD. The purpose of the program is to enhance shareholder value and stabilizing stock prices. The program will expire on July 20, 2025. As of January 20, 2025, the company had no shares held in treasury within the dividend payable range acquisition and through Other Acquisition. Buy Or Sell Opportunity • Jan 08
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 5.3% to ₩3,185. The fair value is estimated to be ₩2,646, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.6% over the last 3 years. Earnings per share has declined by 27%. New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩44.7b market cap, or US$31.1m). Valuation Update With 7 Day Price Move • Dec 16
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩3,110, the stock trades at a trailing P/E ratio of 18x. Average trailing P/E is 13x in the Life Sciences industry in South Korea. Total loss to shareholders of 26% over the past three years. New Risk • Nov 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩53.0b market cap, or US$37.9m). Valuation Update With 7 Day Price Move • Nov 20
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to ₩3,685, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 13x in the Life Sciences industry in South Korea. Total loss to shareholders of 14% over the past three years. New Risk • Sep 17
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩44.9b market cap, or US$34.1m). Reported Earnings • Mar 12
Full year 2023 earnings released: EPS: ₩225 (vs ₩324 in FY 2022) Full year 2023 results: EPS: ₩225. Revenue: ₩15.2b (up 11% from FY 2022). Net income: ₩3.24b (up 39% from FY 2022). Profit margin: 21% (up from 17% in FY 2022). The increase in margin was driven by higher revenue. New Risk • Oct 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (16% net profit margin). Market cap is less than US$100m (₩67.2b market cap, or US$49.7m). Valuation Update With 7 Day Price Move • Oct 12
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₩9,910, the stock trades at a trailing P/E ratio of 32.6x. Average trailing P/E is 36x in the Life Sciences industry in South Korea. Total loss to shareholders of 13% over the past three years. Reported Earnings • Mar 14
Full year 2022 earnings released: EPS: ₩324 (vs ₩771 in FY 2021) Full year 2022 results: EPS: ₩324 (down from ₩771 in FY 2021). Revenue: ₩13.8b (up 17% from FY 2021). Net income: ₩2.33b (down 58% from FY 2021). Profit margin: 17% (down from 47% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • May 19
Investor sentiment improved over the past week After last week's 19% share price gain to ₩10,550, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 22x in the Life Sciences industry in South Korea. Total returns to shareholders of 51% over the past three years. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment improved over the past week After last week's 20% share price gain to ₩10,300, the stock trades at a trailing P/E ratio of 13.4x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 47% over the past three years. Valuation Update With 7 Day Price Move • Feb 03
Investor sentiment improved over the past week After last week's 25% share price gain to ₩9,600, the stock trades at a trailing P/E ratio of 17.4x. Average trailing P/E is 24x in the Life Sciences industry in South Korea. Total returns to shareholders of 42% over the past three years. Valuation Update With 7 Day Price Move • Aug 04
Investor sentiment improved over the past week After last week's 17% share price gain to ₩11,600, the stock trades at a trailing P/E ratio of 32.5x. Average trailing P/E is 29x in the Life Sciences industry in South Korea. Total returns to shareholders of 57% over the past three years. Is New 90 Day High Low • Feb 26
New 90-day low: ₩7,370 The company is down 29% from its price of ₩10,450 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 3.0% over the same period. Is New 90 Day High Low • Feb 08
New 90-day low: ₩8,440 The company is down 23% from its price of ₩11,000 on 10 November 2020. The South Korean market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 7.0% over the same period. Duyuru • Feb 02
Aligned Genetics, Inc., Annual General Meeting, Mar 29, 2021 Aligned Genetics, Inc., Annual General Meeting, Mar 29, 2021, at 09:00 Korea Standard Time. Is New 90 Day High Low • Jan 18
New 90-day low: ₩8,980 The company is down 15% from its price of ₩10,600 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 15% over the same period. Is New 90 Day High Low • Dec 22
New 90-day low: ₩9,360 The company is down 22% from its price of ₩12,000 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 14% over the same period. Is New 90 Day High Low • Oct 26
New 90-day low: ₩9,940 The company is down 3.0% from its price of ₩10,300 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 12% over the same period.